SAN DIEGO, July 15, 2026
Sinopia Biosciences announced the publication of preclinical research in Science Translational Medicine supporting SB-0110, a novel PKA-II positive modulator, as a potential treatment for Parkinson’s disease. The study demonstrated that selective modulation of PKA-II enhanced the therapeutic effects of levodopa while reducing levodopa-induced dyskinesia (LID) in highly translatable non-human primate models, addressing one of the most significant treatment challenges in Parkinson’s disease.
SB-0110 Improves Motor Function While Reducing Dyskinesia
The published study showed that SB-0110, together with its predecessor SB-0107, significantly reduced dyskinesia severity while enhancing levodopa’s antiparkinsonian effects in non-human primate models with established Parkinson’s disease. Unlike current adjunctive therapies that often worsen dyskinesia, SB-0110 selectively targets PKA-II, a signaling protein downstream of dopamine receptors, offering a differentiated mechanism designed to improve motor function without increasing treatment-related complications.
Novel Discovery Platform Identifies Differentiated Therapeutic Target
Researchers identified SB-0107 using Sinopia’s proprietary LEADS® (LEarn And DiScover) platform, which integrates high-throughput omics, artificial intelligence, machine learning, and network analysis to identify novel therapeutic candidates. Transcriptomic screening matched drug-induced cellular signatures with Parkinson’s disease treatment profiles, revealing selective PKA-II modulation as a promising strategy. Preclinical testing also demonstrated that SB-0110 showed no meaningful activity across established Parkinson’s disease drug targets, a broad panel of GPCRs, or major off-target safety panels, supporting a favorable safety profile ahead of IND-enabling studies.
Advertisement
SB-0110 Advances Toward First-in-Human Development
SB-0110 is currently progressing through late-stage preclinical toxicology studies, with first-in-human clinical trials anticipated in 2027. The research was supported by the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of General Medical Sciences (NIGMS), and The Michael J. Fox Foundation for Parkinson’s Research. The publication further validates Sinopia’s omics-guided drug discovery approach as a strategy for identifying first-in-class therapies for neurological disorders with significant unmet medical need.
Source: Neutrolis press release
